Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

HUNTSVILLE, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate, SER-252, for advanced Parkinson's disease, enabled by its proprietary POZ Platform^™ drug optimization technology, today announced its financial results for the second quarter ended June 30, 2025, along with key recent updates.

Read more at globenewswire.com